Literature DB >> 27252234

Phenotype and immune function of lymph node and peripheral blood CLL cells are linked to transendothelial migration.

Marta Pasikowska1, Elisabeth Walsby2, Benedetta Apollonio1, Kirsty Cuthill1, Elizabeth Phillips1, Eve Coulter1, Maria Serena Longhi3, Yun Ma3, Deborah Yallop1, Linda D Barber1, Piers Patten1, Chris Fegan2, Alan G Ramsay1, Chris Pepper2, Stephen Devereux1, Andrea G S Buggins1.   

Abstract

Several lines of evidence suggest that homing of tumor cells to lymphoid tissue contributes to disease progression in chronic lymphocytic leukemia (CLL). Here, we demonstrate that lymph node (LN)-derived CLL cells possess a distinct phenotype, and exhibit enhanced capacity for T-cell activation and superior immune synapse formation when compared with paired peripheral blood (PB) samples. LN-derived CLL cells manifest a proliferative, CXCR4(dim)CD5(bright) phenotype compared with those in the PB and higher expression of T-cell activation molecules including CD80, CD86, and HLA-D-related (DR). In addition, LN-CLL cells have higher expression of α4β1 (CD49d) which, as well as being a co-stimulatory molecule, is required for CLL cells to undergo transendothelial migration (TEM) and enter the proliferation centers of the LNs. Using an in vitro system that models circulation and TEM, we showed that the small population of CLL cells that migrate are CXCR4(dim)CD5(bright) with higher CD49d, CD80, CD86, and HLA-DR compared with those that remain circulating; a phenotype strikingly similar to LN-derived CLL cells. Furthermore, sorted CD49d(hi) CLL cells showed an enhanced capacity to activate T cells compared with CD49d(lo) subpopulations from the same patient. Thus, although PB-CLL cells have a reduced capacity to form immune synapses and activate CD4(+) T cells, this was not the case for LN-CLL cells or those with the propensity to undergo TEM. Taken together, our study suggests that CLL cell immunologic function is not only modulated by microenvironmental interactions but is also a feature of a subpopulation of PB-CLL cells that are primed for lymphoid tissue homing and interaction with T cells.
© 2016 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27252234     DOI: 10.1182/blood-2016-01-683128

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

1.  CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression.

Authors:  Erika Tissino; Federico Pozzo; Dania Benedetti; Chiara Caldana; Tamara Bittolo; Francesca Maria Rossi; Riccardo Bomben; Paola Nanni; Hillarj Chivilò; Ilaria Cattarossi; Eva Zaina; Kevin Norris; Jerry Polesel; Massimo Gentile; Giovanni Tripepi; Riccardo Moia; Enrico Santinelli; Idanna Innocenti; Jacopo Olivieri; Giovanni D'Arena; Luca Laurenti; Francesco Zaja; Gabriele Pozzato; Annalisa Chiarenza; Francesco Di Raimondo; Davide Rossi; Chris Pepper; Tanja Nicole Hartmann; Gianluca Gaidano; Giovanni Del Poeta; Valter Gattei; Antonella Zucchetto
Journal:  Blood       Date:  2020-04-09       Impact factor: 22.113

2.  Proteomics Profiling of CLL Versus Healthy B-cells Identifies Putative Therapeutic Targets and a Subtype-independent Signature of Spliceosome Dysregulation.

Authors:  Harvey E Johnston; Matthew J Carter; Marta Larrayoz; James Clarke; Spiro D Garbis; David Oscier; Jonathan C Strefford; Andrew J Steele; Renata Walewska; Mark S Cragg
Journal:  Mol Cell Proteomics       Date:  2018-01-24       Impact factor: 5.911

3.  CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia.

Authors:  Paolo Strati; Sameer A Parikh; Kari G Chaffee; Sara J Achenbach; Susan L Slager; Timothy G Call; Wei Ding; Diane F Jelinek; Curtis A Hanson; Neil E Kay; Tait D Shanafelt
Journal:  Br J Haematol       Date:  2017-04-07       Impact factor: 6.998

Review 4.  In Vitro and In Vivo Models of CLL-T Cell Interactions: Implications for Drug Testing.

Authors:  Eva Hoferkova; Sona Kadakova; Marek Mraz
Journal:  Cancers (Basel)       Date:  2022-06-23       Impact factor: 6.575

5.  Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment.

Authors:  Iris de Weerdt; Tom Hofland; Renate de Boer; Johan A Dobber; Julie Dubois; Denise van Nieuwenhuize; Mehrdad Mobasher; Fransien de Boer; Mels Hoogendoorn; Gerjo A Velders; Marjolein van der Klift; Ester B M Remmerswaal; Frederike J Bemelman; Carsten U Niemann; Sabina Kersting; Mark-David Levin; Eric Eldering; Sanne H Tonino; Arnon P Kater
Journal:  Blood Adv       Date:  2019-09-10

6.  TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target.

Authors:  Emma Kennedy; Eve Coulter; Emma Halliwell; Nuria Profitos-Peleja; Elisabeth Walsby; Barnaby Clark; Elizabeth H Phillips; Thomas A Burley; Simon Mitchell; Stephen Devereux; Christopher D Fegan; Christopher I Jones; Rosalynd Johnston; Tim Chevassut; Ralph Schulz; Martina Seiffert; Angelo Agathanggelou; Ceri Oldreive; Nicholas Davies; Tatjana Stankovic; Triantafillos Liloglou; Chris Pepper; Andrea G S Pepper
Journal:  Blood       Date:  2021-06-03       Impact factor: 22.113

7.  Idelalisib and caffeine reduce suppression of T cell responses mediated by activated chronic lymphocytic leukemia cells.

Authors:  Barry D Hock; Sean A MacPherson; Judith L McKenzie
Journal:  PLoS One       Date:  2017-03-03       Impact factor: 3.240

Review 8.  Paraneoplastic Pemphigus: Paraneoplastic Autoimmune Disease of the Skin and Mucosa.

Authors:  Jong Hoon Kim; Soo-Chan Kim
Journal:  Front Immunol       Date:  2019-06-04       Impact factor: 7.561

9.  In vitro and in vivo evidence for uncoupling of B-cell receptor internalization and signaling in chronic lymphocytic leukemia.

Authors:  Eve M Coulter; Andrea Pepper; Silvia Mele; Najeem'deen Folarin; William Townsend; Kirsty Cuthill; Elizabeth H Phillips; Piers E M Patten; Stephen Devereux
Journal:  Haematologica       Date:  2017-12-14       Impact factor: 9.941

10.  High CXCR3 on Leukemic Cells Distinguishes IgHV mut from IgHV unmut in Chronic Lymphocytic Leukemia: Evidence from CD5high and CD5low Clones.

Authors:  Gayane Manukyan; Tomas Papajik; Zuzana Mikulkova; Renata Urbanova; Veronika Smotkova Kraiczova; Jakub Savara; Milos Kudelka; Peter Turcsanyi; Eva Kriegova
Journal:  J Immunol Res       Date:  2020-06-20       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.